Ir-Med Inc Financials
This page shows Ir-Med Inc (IRME) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Ir-Med Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Ir-Med Inc earned -$0.03 per diluted share (EPS) in fiscal year 2024. This represents an increase of 57.1% from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Ir-Med Inc held $129K in cash as of fiscal year 2024; long-term debt is not reported for that period.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
None of these metrics is reported for fiscal year 2024.
Capital Allocation
Ir-Med Inc invested $710K in research and development in fiscal year 2024. This represents a decrease of 65.6% from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
IRME Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $91K+295.7% | $23K | N/A | $205K+118.1% | $94K-51.8% | $195K | N/A | $469K |
| SG&A Expenses | $194K-14.9% | $228K | N/A | $367K+55.5% | $236K-20.0% | $295K | N/A | $431K |
| Operating Income | -$286K-13.0% | -$253K | N/A | -$601K-67.9% | -$358K+45.6% | -$658K | N/A | -$1.2M |
| Net Income | -$701K | N/A | N/A | -$598K-63.4% | -$366K+44.3% | -$657K | N/A | -$1.2M |
| EPS (Diluted) | -$0.010.0% | -$0.010.0% | -$0.010.0% | -$0.01 | -$0.01 | -$0.01+50.0% | -$0.020.0% | -$0.02 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
IRME Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $175K+41.1% | $124K-50.6% | $251K-52.9% | $533K-39.9% | $887K+53.2% | $579K-42.0% | $999K-43.7% | $1.8M |
| Current Assets | $90K+11.1% | $81K-60.5% | $205K-53.7% | $443K-43.9% | $789K+70.4% | $463K-45.4% | $848K-47.2% | $1.6M |
| Cash & Equivalents | $63K+23.5% | $51K-60.5% | $129K-67.1% | $392K-47.9% | $753K+84.6% | $408K-46.8% | $767K-49.7% | $1.5M |
| Accounts Receivable | $27K-10.0% | $30K-60.5% | $76K+49.0% | $51K+41.7% | $36K-34.5% | $55K-32.1% | $81K-2.4% | $83K |
| Total Liabilities | $800K+29.7% | $617K+13.2% | $545K+2.6% | $531K+1.3% | $524K-21.2% | $665K+4.9% | $634K+13.0% | $561K |
| Current Liabilities | $774K+25.4% | $617K+13.2% | $545K | N/A | N/A | N/A | $473K-15.4% | $559K |
| Total Equity | -$625K-26.8% | -$493K-67.7% | -$294K-14800.0% | $2K-99.4% | $363K+522.1% | -$86K-123.6% | $365K-69.9% | $1.2M |
| Retained Earnings | -$18.2M-4.0% | -$17.5M-4.6% | -$16.7M-1.7% | -$16.5M-3.8% | -$15.9M-2.4% | -$15.5M-4.4% | -$14.8M-9.4% | -$13.6M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
IRME Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$71K+35.5% | -$110K+57.9% | -$261K+33.9% | -$395K-6.2% | -$372K-3.9% | -$358K+52.5% | -$754K+7.0% | -$811K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $1K | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$755K | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$1K | N/A |
| Financing Cash Flow | $88K+183.9% | $31K | $0-100.0% | $35K | N/A | N/A | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
IRME Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | N/A | N/A | -29900.0%-29799.2pp | -100.8% | N/A | N/A | -97.3% |
| Return on Assets | -400.6% | N/A | N/A | -112.2%-70.9pp | -41.3%+72.2pp | -113.5% | N/A | -66.5% |
| Current Ratio | 0.120.0x | 0.13-0.2x | 0.38 | N/A | N/A | N/A | 1.79-1.1x | 2.87 |
| Debt-to-Equity | N/A | N/A | N/A | 265.50+264.1x | 1.44 | N/A | 1.74+1.3x | 0.46 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$294K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.38), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Ir-Med Inc Ranks
Frequently Asked Questions
What are Ir-Med Inc's total assets?
Ir-Med Inc (IRME) had $251K in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Ir-Med Inc spend on research and development?
Ir-Med Inc (IRME) invested $710K in research and development during fiscal year 2024.
What is Ir-Med Inc's current ratio?
Ir-Med Inc (IRME) had a current ratio of 0.38 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
Why is Ir-Med Inc's debt-to-equity ratio negative or not reported?
Ir-Med Inc (IRME) has negative shareholder equity of -$294K as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.